AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

2(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

3(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

4(Currently Amended). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:




I

wherein:

$R^1$ and $R^2$ are joined to form ~~a ring selected from the group consisting of~~

-$CH_2(CH_2)_nCH_2$-, -$CH_2CH_2C(CH_3)_2CH_2CH_2$-, -$O(CH_2)_mCH_2$-, -$O(CH_2)_pO$-, -$CH_2CH_2OCH_2CH_2$-, -$CH_2CH_2N(H)CH_2CH_2$-, and -$CH_2CH_2N(alkyl)CH_2CH_2$-;

m is an integer from 1 to 4;

n is an integer from 1 4 or to 5;

p is an integer from 1 to 4;

or $R^1$ and $R^2$ form a double bond to $C(CH_3)_2$, C(cycloalkyl), O, or C(cycloether);

$R^3$ is selected from the group consisting of H, OH, $NH_2$, $C_1$ to $C_6$ alkyl, substituted $C_1$ to $C_6$ alkyl, $C_3$ to $C_6$ alkenyl, substituted $C_3$ to $C_6$ alkenyl, alkynyl, substituted alkynyl, and $COR^A$;

$R^A$ is selected from the group consisting of H, $C_1$ to $C_3$ alkyl, substituted $C_1$ to $C_3$ alkyl, $C_1$ to $C_3$ alkoxy, substituted $C_1$ to $C_3$ alkoxy, $C_1$ to $C_3$ aminoalkyl, and substituted $C_1$ to $C_3$ aminoalkyl;

$R^4$ is selected from the group consisting of H, halogen, CN, $NH_2$, $C_1$ to $C_6$ alkyl, substituted $C_1$ to $C_6$ alkyl, $C_1$ to $C_6$ alkoxy, substituted $C_1$ to $C_6$ alkoxy, $C_1$ to $C_6$ aminoalkyl, and substituted $C_1$ to $C_6$ aminoalkyl;

$R^5$ is a five membered heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, $SO_2$ and $NR^6$ and having one or two independent substituents from the group consisting of H, halogen, CN, $NO_2$, $C_1$ to $C_3$ $C_4$ alkyl, substituted $C_1$ to $C_4$ alkyl, $C_1$ to $C_3$ alkoxy, substituted $C_1$ to $C_3$ alkoxy, $C_1$ to $C_3$ aminoalkyl, substituted $C_1$ to $C_3$ aminoalkyl, $COR^D$, and $CSR^D$, and $NR^ECOR^D$;

$R^D$ is H, $NH_2$, $C_1$ to $C_3$ alkyl, substituted $C_1$ to $C_3$ alkyl, aryl, substituted aryl, $C_1$ to $C_3$ alkoxy, substituted $C_1$ to $C_3$ alkoxy, $C_1$ to $C_3$ aminoalkyl, or substituted $C_1$ to $C_3$ aminoalkyl;

$R^E$ is H, $C_1$ to $C_3$ alkyl, or substituted $C_1$ to $C_3$ alkyl;

$R^6$ is H, or $C_1$ to $C_3$ alkyl, substituted $C_1$ to $C_3$ alkyl, or $C_1$ to $C_4CO_2$alkyl;

$Q^1$ is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

5(Previously Presented). The method according to claim 4, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

6(Previously Presented). The method according to claim 4, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

7(Previously Presented). The method according to claim 4, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.

8(Canceled).

9(Previously Presented). The method according to Claim 4, wherein ~~$R^1$ and $R^2$ are joined to form the $CH_2(CH_2)_nCH_2$ ring; n is 3;~~ ~~$R^3$ and $R^4$ are H;~~ $R^5$ is the five membered ring having the structure:




U is O, S, or $NR^6$;

X' is selected from the group consisting of halogen, CN, ~~$NO_2$, $CONH_2$;~~ and $CSNH_2$; ~~$COR^B$, $CSR^B$, $C_1$ to $C_3$ alkyl, and $C_1$ to $C_3$ alkoxy;~~

~~$R^B$ is $C_1$ to $C_3$ aminoalkyl or substituted $C_1$ to $C_3$ aminoalkyl, wherein said aminoalkyl is NH(alkyl) or $N(alkyl)_2$;~~

Y' is ~~selected from the group consisting of~~ H, ~~halogen, and $C_1$ to $C_4$ alkyl, wherein said halogen is F~~.

10-11(Canceled).

12-13(Canceled).

14(Currently Amended). The method according to claim 4, wherein said compound is selected from the group consisting of 4-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile, 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophenethioamide, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, ~~5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-(tert-butoxycarbonyl)-pyrrole-2-carbonitrile,~~ 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-H-pyrrole-2-carbonitrile, 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-3-thiophenecarbonitrile, 5-(1,2-Dihydro-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile, ~~4-(3,3-dimethyl-2-thioxo-2,3-dihydro-1H-indol-5-yl)-2-furonitrile,~~ 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-furancarbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-4-methyl-2-thiophenecarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-2-thiophenecarbonitrile, ~~5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-n-butyl-2-thiophenecarbonitrile,~~ and a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

15-43(Canceled).